Feed / EYPT

EyePoint, Inc.

EYPT

Healthcare · 6.18 -56.8% today

Participation confirmed · construction unavailableMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

EyePoint, Inc.'s move is being confirmed by its market group.

No new filing conclusion is available. 14 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.

Company-56.8% todayVolume comparison unavailable
Market group14 of 18 activeBiotech Rare Diseases · active
Disclosed network0 of 1 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 12 of 18 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ROIV begins moving with the group.

Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.

Watch this read

Who this business touches

The relationships behind EYPT

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depended on by

FDMT4D Molecular Therapeutics, Inc.competitorMar 18, 2026 ▾

“We also face competition from late-stage sustained release VEGF receptor tyrosine kinase 11 inhibitor programs at EyePoint Inc.”

Filing peers

ASPNSBHUMBF

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

EYPT is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.